2025
Role of Chimeric Antigen Receptor–Expressing Cell Therapy in Immune-Mediated Kidney Diseases: A Review
Peng J, Zhang Y, Wang J, Zhang H, Schett G. Role of Chimeric Antigen Receptor–Expressing Cell Therapy in Immune-Mediated Kidney Diseases: A Review. American Journal Of Kidney Diseases 2025 PMID: 40484342, DOI: 10.1053/j.ajkd.2025.04.012.Peer-Reviewed Original ResearchImmune-mediated kidney diseasesB-cell depletionB cellsKidney diseaseCell therapyPlasma cellsTreatment of immune-mediated kidney diseasesB-cell-depleting monoclonal antibodyB-Cell Targeted TherapiesComplete B-cell depletionAutoantibody-producing plasma cellsDeplete plasma cellsMonoclonal antibodiesAntigen-presenting cellsAdaptive immune responsesImmune-mediatedSelf-antigensT cellsImmune cellsImmune responseTherapyInfiltrated tissuesDiseaseAntibodiesCells
2020
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
Gauckler P, Shin J, Alberici F, Audard V, Bruchfeld A, Busch M, Cheung C, Crnogorac M, Delbarba E, Eller K, Faguer S, Galesic K, Griffin S, Hrušková Z, Jeyabalan A, Karras A, King C, Kohli H, Maas R, Mayer G, Moiseev S, Muto M, Odler B, Pepper R, Quintana L, Radhakrishnan J, Ramachandran R, Salama A, Segelmark M, Tesař V, Wetzels J, Willcocks L, Windpessl M, Zand L, Zonozi R, Kronbichler A, group F. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown? Autoimmunity Reviews 2020, 19: 102671. PMID: 32942039, DOI: 10.1016/j.autrev.2020.102671.Peer-Reviewed Original ResearchConceptsFocal segmental glomerulosclerosisSegmental glomerulosclerosisB-cell-depleting monoclonal antibodyAdult minimal change diseaseSteroid-sparing therapyToxic immunosuppressive agentsLow level of evidenceLong-term efficacyMinimal change diseaseLevel of evidenceRituximab-treatmentRandomized Controlled TrialsImmunosuppressive treatmentSteroid-dependentImmunosuppressive agentsOptimal regimenMulticenter studyNephrotic syndromeAdult patientsChange diseaseDisease courseOff-labelSide effectsControlled TrialsMonoclonal antibodies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply